FDA approves Bristol-Myers Squibb’s Opdivo injection to treat mUC Bristol-Myers Squibb’s Opdivo injection (nivolumab) has been approved by U.S. FDA for intravenous use in previously treated, locally advanced or metastatic urothelial carcinoma (mUC), a type of bladder cancer. This indication is approved based on tumo...
Find MoreLive Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!